23:19 , May 3, 2018 |  BC Extra  |  Preclinical News

Heterologous, autologous cell therapy could treat hemophilia B

A study published in Cell Reports from researchers at Salk Institute for Biological Studies suggests that heterologous and autologous cell therapy could help treat hemophilia B. Hemophilia B is characterized by a systemic lack of...
16:33 , Jan 26, 2018 |  BC Week In Review  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Jan. 19,...
19:50 , Jan 22, 2018 |  BC Extra  |  Company News

Sanofi acquiring Bioverativ for $11.6B

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire hematology company Bioverativ Inc. (NASDAQ:BIVV) for $105 per share in cash, or $11.6 billion. The price is a 64% premium to Bioverativ's close of $64.11 on Friday before...
01:27 , Jan 13, 2018 |  BioCentury  |  Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
18:02 , Sep 1, 2017 |  BC Week In Review  |  Company News

Shire partners with MicroHealth to develop hemophilia tool

Shire plc (LSE:SHP; NASDAQ:SHPG) said it is collaborating with digital health company MicroHealth LLC (Vienna, Va.) to customize MicroHealth's existing monitoring tool for use among hemophilia A and B patients who have developed neutralizing antibodies...
22:16 , Aug 25, 2017 |  BC Extra  |  Company News

Shire and MicroHealth partner to develop hemophilia tool

Shire plc (LSE:SHP; NASDAQ:SHPG) said it is collaborating with digital health company MicroHealth LLC (Vienna, Va.) to customize MicroHealth's existing monitoring tool for use among hemophilia A and B patients who have developed neutralizing antibodies...
12:24 , May 26, 2017 |  BC Week In Review  |  Company News

Bioverativ aquiring True North

Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009 , which has completed a Phase Ib trial...
21:23 , May 23, 2017 |  BC Extra  |  Company News

Bioverativ acquiring True North

Bioverativ Inc. (NASDAQ:BIVV) said it will acquire rare disease company True North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009 , which has completed a Phase Ib study...
00:26 , Apr 15, 2017 |  BioCentury  |  Product Development

Outside factors

This year could see the first regulatory submission from a coming wave of new therapies for hemophilia prophylaxis that do not simply replace missing clotting factors, which has been the standard for care for decades....
02:38 , Feb 11, 2017 |  BioCentury  |  Strategy

Building Bioverativ

Biogen Inc. ’s newly minted hematology spinout Bioverativ Inc. will have at least three years to build market share for its hemophilia therapies and flesh out its pipeline before gene therapies potentially hit the market....